GlassScriptPhysician profile
Ryan Joseph Matherne
NPI 1528259710
$8,892.96
in general payments reported to CMS, 2019-2025
32 companies · $2,204 in 2025
The $2,204 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $246 · 2021: $930 · 2022: $2,048 · 2023: $1,731 · 2024: $1,360 · 2025: $2,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,826 · Education: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,825.57 |
| Education | $470.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,830.29 | 2019-2025 | |
| Janssen Biotech, INC. | $1,168.51 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $1,168.46 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $586.53 | 2021-2025 | Dupixent |
| Ucb, INC. | $559.04 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $444.24 | 2019-2023 | Winlevi, Absorica Ld, Ilumya |
| Novartis Pharmaceuticals Corporation | $411.74 | 2019-2023 | |
| Pfizer INC. | $382.15 | 2019-2025 | |
| Lilly USA, LLC | $316.90 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Organogenesis INC. | $279.89 | 2023-2024 | Puraply, Affinity, Puraply Franchise |
| E.R. Squibb & Sons, L.L.C. | $279.19 | 2022-2025 | Sotyktu |
| Merz North America, INC. | $219.39 | 2022 | |
| Leo Pharma INC. | $199.92 | 2021-2025 | Adbry |
| Amgen INC. | $189.17 | 2020-2025 | Otezla, Otezla |
| Hill Dermaceuticals, INC. | $91.44 | 2025 | Tolak |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $87.28 | 2020-2025 | Seysara |
| Incyte Corporation | $81.10 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $70.38 | 2023-2025 | Zoryve |
| Medimetriks Pharmaceuticals, INC. | $61.67 | 2022 | |
| Dermavant Sciences, INC. | $61.28 | 2023-2024 | Vtama |
| Organon LLC | $60.85 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $59.42 | 2021-2025 | Aklief |
| Vyne Pharmaceuticals INC. | $58.09 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.66 | 2019-2023 | Jublia, Arazlo, Duobrii |
| Genentech USA, INC. | $46.50 | 2019-2021 | |
| Journey Medical Corporation | $37.48 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $23.79 | 2022 | |
| Revance Therapeutics, INC. | $18.92 | 2024 | Daxxify |
| Mallinckrodt Hospital Products INC. | $16.07 | 2024 | Acthar |
| Botanix Sb INC | $13.87 | 2025 | Sofdra |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Reprise Biomedical, INC. | $6.57 | 2025 | Mirodry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Matherne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.